ClinicalTrials.gg
Active, not recruitingNCT06685757TRANSCENDUpdated Jun 5, 2026

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

A Phase 3 interventional study of Felzartamab and Placebo in Antibody-mediated Rejection, sponsored by Biogen. Active, not recruiting at 56 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney.

Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In people with AMR, these antibodies mistakenly see the new organ as a threat and damage its blood vessels. This can cause the new organ to fail.

In this study, researchers will learn more about how a study drug called felzartamab affects people with AMR. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works in participants with kidney transplants who experience AMR compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. All participants in this study will have active AMR or AMR that has lasted for at least 6 months after their kidney transplant.

The main question that researchers want to answer is:

  • How many participants have biopsy results showing that their transplanted kidney tissue looks normal or near normal after 24 weeks of treatment?

Researchers will also learn about:

  • How long it takes before the participants' disease gets worse
  • How long the participants' urine protein levels stay low
  • Kidney biopsy scores to check for blood vessel inflammation at 6 months and 1 year
  • How many people have no blood vessel inflammation at these times
  • Changes in donor deoxyribonucleic acid (DNA) levels in blood from the start of treatment
  • Biopsy test scores for signs of rejection and inflammation at 6 months and 1 year
  • Changes in kidney function from the start of treatment
  • How many people have biopsy results showing their kidney tissue looks normal again
  • How long the transplanted kidney keeps working
  • How many participants have medical problems during the study
  • How many participants show signs of another type of kidney transplant rejection called T-cell-mediated rejection (TCMR) at Week 24 and Week 52
  • How do results from vital signs, electrocardiograms (ECGs), and blood and urine tests change over time
  • How felzartamab is processed by the body
  • How many participants develop antibodies against felzartamab in the blood

The study will be done as follows:

  • Participants will be screened to check if they can join the study. This will take up to 42 days.
  • There will be 2 parts in this study.
  • Part A of the study is "double blind." This means that neither the participants, study doctor, or site staff know if the participants received the study drug or a placebo. During Part A, participants will be randomized to receive up to 9 doses of either felzartamab or placebo.
  • Part B of the study is "open label." This means that the participants, study doctor, and site staff know which study drug the participant is receiving. During Part B, all participants from Part A will receive up to 9 doses of felzartamab.
  • All doses will be given through an "intravenous" infusion. This means it will be given into a vein. The dose the participants receive will depend on their body weight.
  • Part A will last up to 24 weeks. Part B will last up to 28 weeks. In total, participants will have up to 21 study visits and will be in the study for about 1 year.
Read the detailed description

The primary objective of this study is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with active or chronic active AMR.

The secondary objectives of this study are: Part A: To evaluate the efficacy of felzartamab compared to placebo through additional clinical endpoints; Part B: To summarize felzartamab efficacy at Week 52 in kidney transplant recipients diagnosed with active or chronic active AMR; Parts A and B: To evaluate the safety of felzartamab in kidney transplant recipients diagnosed with active or chronic AMR and to assess the pharmacokinetic (PK) profile and immunogenicity of felzartamab.

02

Conditions studied

  • Antibody-mediated Rejection

Keywords

  • AMR
  • Felzartamab
  • Kidney Transplant
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Active or chronic active AMR (-confirmed) without TCMR per central reading, as defined by the Banff 2022 criteria.
  • Kidney transplant at least 6 months prior to Screening visit (recipients of either living or deceased donors).
  • Donor-specific antibody (DSA): Human leukocyte antigen (HLA) Class I and/or II antigen-specific DSA-positive (preformed and/or de novo DSA) as determined by the local laboratory's definition of positivity using singleantigen bead-based assays within 3 months prior to randomization.

Key Exclusion Criteria:

  • Transplant: Blood type (ABO)-incompatible transplant.
  • History of multiple organ transplants including en bloc and dual kidney transplants.
  • Acute, rapid decline in renal function, defined as a participant likely to require renal replacement therapy within the subsequent 30 days as determined by the Investigator.
  • Treatment: Prior AMR/TCMR treatment (with the exception of ) within 3 months prior to randomization is excluded as listed below. Participants who received any of these treatments between 3 and 6 months prior to randomization must have both a renal biopsy (IC3) and DSA testing at least 6 weeks after completing (or stopping) treatment in order to confirm continuing AMR and to determine eligibility:

    1. Intravenous or subcutaneous immunoglobulin (IVIg or subcutaneous immunoglobulin [SCIg]) or PLEX.
    2. Complement system inhibitors (e.g., eculizumab).
    3. Proteasome inhibitors (e.g., bortezomib).
    4. Tocilizumab.
    5. Any B cell-depleting therapy (including anti-Cluster of Differentiation 20 [CD20] agents [e.g., rituximab]) within 3 months prior to randomization.
    6. Any other agent within 3 months or 5 half-lives (whichever is longer) of randomization.

Note: Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Felzartamab

    Drug: Felzartamab

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants will receive felzartamab by intravenous infusion.

    Also known as: MOR202, MOR03087, TJ202, HIB202, BIIB148

  • DrugPlacebo

    Participants will receive 0.9% saline solution by intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)

    Time frame: Week 24

Secondary outcomes

  1. Part A: Microvascular Inflammation (MVI) Score

    Time frame: Week 24

  2. Part A: Percentage of Participants Who Achieve an MVI Score of 0

    Time frame: Week 24

  3. Part A: Change from Baseline in Donor-derived Cell-free DNA (dd-cfDNA)

    Time frame: Baseline, Week 24

  4. Part A: Biopsy-based Transcript Composite Score for AMR/MVI

    Time frame: At Week 24

  5. Part A: Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline, Week 24

  6. Part B: Percentage of Participants Who Achieve BPHR

    Time frame: Weeks 24 and 52

  7. Part B: MVI Score

    Time frame: Weeks 24 and 52

  8. Part B: Percentage of Participants Who Achieve an MVI Score of 0

    Time frame: Weeks 24 and 52

  9. Part B: Change from Baseline in dd-cfDNA

    Time frame: Baseline, Weeks 24 and 52

  10. Part B: Biopsy-based Transcript Composite Score for AMR/MVI

    Time frame: At Week 52

  11. Part B: Change from Baseline in eGFR

    Time frame: Baseline, Weeks 24 and 52

  12. Part B: Time to All-cause Allograft Loss

    Time frame: Up to Week 52

  13. Parts A and B: Number of Participants with Adverse Events

    Time frame: From time of first dose to end of trial visit (Up to Week 52)

  14. Parts A and B: Number of Participants with Clinically Significant Laboratory Abnormalities

    Time frame: From time of first dose to end of trial visit (Up to Week 52)

  15. Parts A and B: Number of Participants with Clinically Significant Vital Signs Abnormalities

    Time frame: From time of first dose to end of trial visit (Up to Week 52)

  16. Parts A and B: Number of Participants with Clinically Significant ECG Abnormalities

    Time frame: From time of first dose to end of trial visit (Up to Week 52)

  17. Parts A and B: Percentage of Participants with T Cell-mediated Rejection (TCMR) by Biopsy

    Time frame: Weeks 24 and 52

  18. Parts A and B: Felzartamab Serum Concentration

    Time frame: Up to Week 52

  19. Parts A and B: Number of Participants with Anti-drug Antibodies (ADAs) against Felzartamab

    Time frame: Baseline, up to Week 52

07

Study locations

56 sites
08

References and documents

Publications

  • Bohmig GA, Akifova A, Budde K. World Transplant Congress 2025 Highlights: Immunosuppression. Transplantation. 2026 Feb 1;110(2):e356-e362. doi: 10.1097/TP.0000000000005569. Epub 2025 Dec 23. PubMed 41430762 ↗
  • Mayer KA, Budde K, Diebold M, Halloran PF, Bohmig GA. Targeting CD38 in Antibody-Mediated Rejection. Transpl Int. 2025 May 15;38:14343. doi: 10.3389/ti.2025.14343. eCollection 2025. PubMed 40444214 ↗

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 12, 2024
StartActual
Dec 3, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06685757
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Dec 3, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion